Analysis of immune cells shows shifts in T cell and B cell responses in bacterial pneumonia, suggesting new therapeutic targets.
Bacterial pneumonia poses a substantial global health burden, yet the immunological mechanisms driving disease pathogenesis and resolution are incompletely understood. We generated a large-scale single-cell transcriptomic atlas of peripheral blood immune cells from 100 individuals: 39 with severe bacterial pneumonia, 31 with mild disease, and 30 healthy controls. Integrating scRNA-seq with clinical and molecular data revealed profound remodeling of the peripheral immune landscape across disease severities. Severe pneumonia was characterized by lymphopenia and monocytosis, accompanied by distinct shifts in T cell, B cell, and myeloid cell subset composition. Classical monocytes emerged as central orchestrators of the cytokine storm observed in severe cases, displaying elevated expression of pro-inflammatory genes (e.g., S100A8/9/12) and enhanced TLR4-MYD88 signaling. Exhaustion of innate-like CD8+ T cells, marked by upregulation of canonical inhibitory receptors, was a hallmark of severe disease. In contrast, mild pneumonia exhibited robust CD8+ T effector and helper memory cell activation, along with effective humoral immunity, evidenced by plasma cell expansion and coordinated Tfh-B cell interactions. B cells in mild cases showed enhanced antigen recognition, BCR signaling, and co-stimulatory gene expression, whereas those in severe cases displayed signs of dysfunction. Myeloid cell alterations in severe pneumonia included increased monocytic MDSCs and non-classical monocytes, contributing to immunosuppression and complement overactivation, respectively. This high-resolution atlas of peripheral immune responses in bacterial pneumonia identifies key cellular and molecular drivers of disease severity, providing potential therapeutic targets for immunomodulation and improved outcomes. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: